Completed PHASE4 INTERVENTIONAL 2-arm NCT02433678

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

Sponsor: Kaleida Health

Updated 7 times since 2017 Last updated: Oct 29, 2019 Started: Nov 30, 2015 Primary completion: Mar 31, 2018 Completion: Nov 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Type 2 Diabetes and is currently completed. Kaleida Health leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Nov 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Dec 2018 — Nov 2019 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Dec 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kaleida Health
University at Buffalo

Data source: University at Buffalo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States